Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Read More
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference Read More
Alkermes Announces Updates to Executive Leadership Team Read More
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831 Read More